ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Robert Cooper, Regional Cancer Center Director, Dead At 59; NCI Critic Epstein Invited to NCAB

April 3, 1992

In Brief: GM awards Shared By Six Scientists; Pollard Named President of Salk Institute

June 21, 1996

In Brief: La Jolla Foundation Receives Donated Buildings; Sinks Named Medical Director, Middlesex Hospital

April 27, 1990

Oral UFT Equivalent To FULV In Stage II and III Colon Cancer

July 30, 2004

Zometa Better Than Placebo In Treatment Of Bone Mets

August 31, 2001

Chabner On Taxol, NSABP: “Makes You Lose Confidence In The Political Process”

May 12, 1995